5,8-dimethoxy-3-methyl-2-tetralone | 251974-89-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 5,8-dimethoxy-3-methyl-2-tetralone
• 英文别名: 5,8-dimethoxy-3-methyl-3,4-dihydro-1H-naphthalen-2-one
• CAS: 251974-89-7
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: UXSXWUZYDJNSIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,8-dimethoxy-3-methyl-2-tetralone 在 氢溴酸 、 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 水 、 乙腈 为溶剂， 生成 trans-5,8-dihydroxy-3-methyl-2-dipropylamino-1,2,3,4-tetrahydronaphthalene
  参考文献：
  名称：

  Synthesis of (−)-5,8-Dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: An Inhibitor of β-Amyloid1–42 Aggregation

  摘要：

  A concise synthesis of the beta-amyloid(1-42) aggregation inhibitor (-)-5,8-dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene [(-)-2] has been developed. The key step is a regio- and diastereoselective hydroboration-amination sequence to convert alkene 6 into amine 9. Enantiomeric resolution was achieved by recrystallization of amine 9 as the dibenzoyl-D-tartaric acid salt. Hydroquinone 2 is a potent inhibitor of the fibrillar aggregation of beta-amyloid as determined in two different assay systems. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00251-1
• 作为产物：
  描述：

  1,4-二氢-5,8-二甲氧基-2-甲基萘 在 硼烷四氢呋喃络合物 、 草酰氯 、 二甲基亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.75h， 生成 5,8-dimethoxy-3-methyl-2-tetralone
  参考文献：
  名称：

  Synthesis of (−)-5,8-Dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: An Inhibitor of β-Amyloid1–42 Aggregation

  摘要：

  A concise synthesis of the beta-amyloid(1-42) aggregation inhibitor (-)-5,8-dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene [(-)-2] has been developed. The key step is a regio- and diastereoselective hydroboration-amination sequence to convert alkene 6 into amine 9. Enantiomeric resolution was achieved by recrystallization of amine 9 as the dibenzoyl-D-tartaric acid salt. Hydroquinone 2 is a potent inhibitor of the fibrillar aggregation of beta-amyloid as determined in two different assay systems. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00251-1

文献信息

• METHOD OF TREATING NEURODEGENERATIVE DISORDERS VIA INHIBITION OF AMYLOID BETA PEPTIDE BINDING
  申请人：——

  公开号：US20020013374A1

  公开（公告）日：2002-01-31

  The invention is directed to a method of treating a neurodegenerative disorder in a subject in need thereof which comprises administering to the subject an amount of a compound effective to inhibit the interaction of amyloid-beta with alpha-7 nicotinic acetylcholine receptors.

  本发明涉及一种治疗神经退行性疾病的方法，包括向需要治疗的受体注射足够的化合物，以抑制淀粉样蛋白-β与α-7尼古丁乙酰胆碱受体的相互作用。
• Method for treating neurodegenerative disorders
  申请人：——

  公开号：US20030130165A1

  公开（公告）日：2003-07-10

  The invention is directed to a method of treating a neurodegenerative disorder in a subject in need thereof which comprises administering to the subject an amount of a compound effective to inhibit the interaction of amyloid-beta with alpha-7 nicotinic acetylcholine receptors.

  本发明涉及一种治疗神经退行性疾病的方法，包括向需要治疗的受体中注射一定量的化合物，以抑制淀粉样蛋白β与α-7尼古丁乙酰胆碱受体的相互作用。
• Method of treating neurodegenerative disorders via inhibition of amyloid beta peptide binding
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06441049B2

  公开（公告）日：2002-08-27

  The invention is directed to a method of treating a neurodegenerative disorder in a subject in need thereof which comprises administering to the subject an amount of a compound effective to inhibit the interaction of amyloid-beta with alpha-7 nicotinic acetylcholine receptors.

  本发明涉及一种治疗神经退行性疾病的方法，包括向需要治疗的受体中注射一定量的化合物，该化合物能够有效抑制淀粉样蛋白-β与α-7型尼古丁乙酰胆碱受体的相互作用。
• METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1083889A2

  公开（公告）日：2001-03-21
• TETRAHYDRONAPHTALENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1083889B1

  公开（公告）日：2003-12-10